EntryPoint Capital’s 10x Genomics TXG Stock Holding History

EntryPoint Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,472	Closed	-$239K	–	860
2025 Q3	$239K	Sell	20,472 -27,155	-57%	-$354K	0.09%	475
2025 Q2	$552K	Sell	47,627 -510	-1%	-$4.65K	0.28%	66
2025 Q1	$420K	Buy	+48,137	New	+$607K	0.19%	166
2024 Q3	–	Sell	-872	Closed	-$17K	–	1147
2024 Q2	$17K	Sell	872 -6,717	-89%	-$176K	0.02%	727
2024 Q1	$285K	Buy	7,589 +7,190	+1,802%	+$316K	0.26%	35
2023 Q4	$22.3K	Buy	+399	New	+$17.4K	0.02%	1019

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EntryPoint Capital's TXG Position: Q4 2025 in Review

EntryPoint Capital sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 20,472 shares — an estimated $239K sold.

EntryPoint Capital first reported a position in TXG in Q4 2023 and held it in 6 quarters. The position peaked at $552K in Q2 2025. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

EntryPoint Capital reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
EntryPoint Capital sold 20,472 10x Genomics shares in Q4 2025, an estimated $239K.
EntryPoint Capital first reported a position in 10x Genomics in Q4 2023 and held it in 6 quarters.
EntryPoint Capital's 10x Genomics position peaked at $552K in Q2 2025.
322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on EntryPoint Capital's 13F filing for Q4 2025, filed 12 Feb 2026.